Replies to post #502050 on Anavex Life Sciences Corp (AVXL)

[hnbadger1]

A repost of Jesse’s post on ST on 8/31/25 for people that upset about what the p2 was intended to accomplish!

MayoMobile 8/31/25, 10:54 PM
SAVXL @mqwlaser
Don and I have collaborated at decent length to come to these conclusions. The 3-71 trial is studying safety in stable schizophrenia patients. The novel mechanism of 3-71 is of such high magnitude (strength via exceedingly high binding) that the company needed to be sure of safety - especially since part A was technically still dose-finding.
EEG biomarkers for schizophrenia are new 2025 technological advances. Some of you will remember the ERP Biomarker Qualification Consortium and Anavex's involvement.
Confirmation of positive, negative, and cognitive electrical biomarkers (EEG) improvement for blinded part B that we've already seen a bit of in part A along with CONSISTENT stabilization in these patients will be key.
PANSS and cognitive improvement in
"secondary outcomes" may only trend in benefit. As mentioned by Don, these patients are already stable, so improvement would likely be low magnitude and might not hit stat sig - which wasn't the intent of trial.
Bullish
BULLISH

[ignatiusrielly35]

It was a marginally important event. It was never going to be anything more than that unless the efficacy results were astounding such that they were stat sig. irrelevant news, basically. What matters is the EMA. 

[Phoenix64]

Why should AVXL release the full data on schizophrenia to the likes of you and your hedge fund manipulators? Regardless of what PR the company is relentlessly attacked. Longs have seen this for years. The PR looked great to me. Four PRs in less than a month and we have cry babies like you. George is looking really good here.

[BIOChecker4]

Yes, but what about Ern?

[skitahoe]

I'm not a technical judge, much of the report is Greek to me. That said, the report was submitted to one of the AI sites and it saw it as quite positive.

For top line data it probably provided about as much as most do, the question is whether a peer review presentation or article will be done, which will provide the data that's wanted.

Gary